Search

everythinglearnresearchcommunity

for

Search:↓

The user discusses using compounded oral minoxidil due to the ineffectiveness and inconvenience of topical minoxidil for diffuse thinning. They question the efficacy of compounded minoxidil compared to original tablet forms and express concerns about the importance of excipients and binders.

Exosomes, cetirizine, melatonin, latanoprost, and caffeine are discussed as potential hair loss treatments. There is skepticism about the effectiveness of exosomes, especially in topical form, but some users report positive results.

Kintor Pharmaceutical's Phase 2 results with the drug Pyrilutamide, a potential alternative to 5-ARI drugs like Finasteride and Dutasteride but without the side effects. It could be used in combination with other topical treatments such as Minoxidil. The safety of the drug has been demonstrated in 6 months of use, however there are still questions about long term efficacy and systemic absorption.

The conversation discusses the potential of PP405 as a hair loss treatment, with some users expressing skepticism and others hopeful about its development. There is also mention of other treatments like Minoxidil, Finasteride, and Pyrilutamide, with users debating the effectiveness and safety of self-experimentation versus waiting for clinical trial results.

The user is experiencing side effects from Dutasteride 0.5 mg and is considering reducing its frequency or switching back to Finasteride, while continuing with Minoxidil 2.5 mg to preserve their hairline. They are unsure if the increased Minoxidil dose is sufficient for regrowth.

The user is using RU58841, Minoxidil, and weekly microneedling for hair loss, having stopped finasteride due to side effects like low libido and depression. They are considering dutasteride as an alternative but are cautious due to past experiences with DHT blockers.

The user is considering using only minoxidil for hair loss due to financial constraints and is unsure if finasteride is necessary. They are also donating blood for money and cannot afford to stop.

A user, 18, is considering switching from topical finasteride (0.025%) and minoxidil to dutasteride due to continued hair shedding. Other users shared their experiences with dutasteride, noting potential benefits and risks, including reduced sperm count.

Finasteride is not linked to a 60% risk of persistent sexual dysfunction; this figure applies only to those already experiencing sexual issues. Most users do not have side effects, and the study's methodology is criticized for selection bias.

People worrying about hair loss and the effects of Finasteride on erections, which a transgirl has experienced no change from taking it with other medications. The discussion suggests that people should stop worrying so much.